151 related articles for article (PubMed ID: 25239870)
1. Tissue composition and density impact on the clinical parameters for (125)I prostate implants dosimetry.
Oliveira SM; Teixeira NJ; Fernandes L; Teles P; Vieira G; Vaz P
Phys Med; 2014 Nov; 30(7):799-808. PubMed ID: 25239870
[TBL] [Abstract][Full Text] [Related]
2. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
5. Investigation of interseed attenuation and tissue composition effects in (125)I seed implant prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Brachytherapy; 2014; 13(6):603-10. PubMed ID: 24913435
[TBL] [Abstract][Full Text] [Related]
6. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.
Fröhlich G; Agoston P; Lövey J; Somogyi A; Fodor J; Polgár C; Major T
Strahlenther Onkol; 2010 Jul; 186(7):388-95. PubMed ID: 20582396
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.
Collins Fekete CA; Plamondon M; Martin AG; Vigneault É; Verhaegen F; Beaulieu L
Med Phys; 2014 Oct; 41(10):101704. PubMed ID: 25281943
[TBL] [Abstract][Full Text] [Related]
10. Loose versus stranded seeds in permanent prostate brachytherapy: dosimetric comparison of intraoperative plans.
Major T; Agoston P; Fröhlich G; Baricza K; Szabo Z; Jorgo K; Herein A; Polgar C
Phys Med; 2014 Dec; 30(8):909-13. PubMed ID: 25175151
[TBL] [Abstract][Full Text] [Related]
11. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.
White EC; Kamrava MR; Demarco J; Park SJ; Wang PC; Kayode O; Steinberg ML; Demanes DJ
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):543-8. PubMed ID: 22652111
[TBL] [Abstract][Full Text] [Related]
12. Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.
Miksys N; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):606-615. PubMed ID: 28126308
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dosimetric effects of metallic artifact reduction and tissue assignment on Monte Carlo dose calculations for
Assam I; Vijande J; Ballester F; Pérez-Calatayud J; Poppe B; Siebert FA
Med Phys; 2022 Sep; 49(9):6195-6208. PubMed ID: 35925023
[TBL] [Abstract][Full Text] [Related]
14. Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.
Chng N; Spadinger I; Rasoda R; Morris WJ; Salcudean S
Med Phys; 2012 Feb; 39(2):721-31. PubMed ID: 22320782
[TBL] [Abstract][Full Text] [Related]
15. Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution.
Rutten TP; Lawson JM; Marcu LG
Phys Med; 2013 Nov; 29(6):662-9. PubMed ID: 22975428
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy.
Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
Radiat Oncol; 2017 Dec; 12(1):192. PubMed ID: 29191234
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry modeling for focal high-dose-rate prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Thwaites D; Henry A
Brachytherapy; 2014; 13(6):611-7. PubMed ID: 25085456
[TBL] [Abstract][Full Text] [Related]
18. Impact of interseed attenuation and tissue composition for permanent prostate implants.
Carrier JF; Beaulieu L; Therriault-Proulx F; Roy R
Med Phys; 2006 Mar; 33(3):595-604. PubMed ID: 16878563
[TBL] [Abstract][Full Text] [Related]
19. The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy.
Duque AS; Corradini S; Kamp F; Seidensticker M; Streitparth F; Kurz C; Walter F; Parodi K; Verhaegen F; Ricke J; Belka C; Fonseca GP; Landry G
Radiat Oncol; 2020 Mar; 15(1):60. PubMed ID: 32151255
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
